Bristol-Myers Squibb (NYSE:BMY) had its price objective dropped by stock analysts at BMO Capital Markets from $52.00 to $51.00 in a research report issued on Tuesday. The brokerage presently has an “underperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price would suggest a potential downside of 13.43% from the company’s current price.
Several other equities analysts have also issued reports on BMY. Leerink Swann reaffirmed a “positive” rating and set a $76.00 price target (up previously from $71.00) on shares of Bristol-Myers Squibb in a research note on Tuesday. Vetr raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 price target on the stock in a research note on Thursday, February 1st. Credit Suisse Group set a $62.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, January 22nd. Piper Jaffray Companies reaffirmed a “hold” rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, January 19th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $65.58.
Bristol-Myers Squibb (NYSE:BMY) traded down $2.05 during trading on Tuesday, reaching $58.91. The company’s stock had a trading volume of 5,983,960 shares, compared to its average volume of 7,643,645. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $96,400.00, a price-to-earnings ratio of 99.85, a P/E/G ratio of 2.19 and a beta of 1.08. Bristol-Myers Squibb has a one year low of $51.12 and a one year high of $66.10.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 4,000 shares of the stock in a transaction on Friday, December 15th. The stock was bought at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the acquisition, the director now directly owns 22,000 shares of the company’s stock, valued at $1,370,600. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
Several institutional investors have recently made changes to their positions in the business. Delphi Private Advisors LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $108,000. Massey Quick Simon & CO. LLC lifted its stake in shares of Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,492 shares during the period. Horan Capital Advisors LLC. acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter valued at about $122,000. Tradewinds Capital Management LLC lifted its stake in shares of Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 500 shares during the period. Finally, Atlantic Trust LLC acquired a new position in shares of Bristol-Myers Squibb in the 2nd quarter valued at about $111,000. Institutional investors own 69.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking and Market News and is the sole property of of American Banking and Market News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/06/bristol-myers-squibb-bmy-price-target-cut-to-51-00.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
